Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody
Clinical and Experimental Medicine · 10.06.2024 · 24 (1)
DOI: 10.1007/s10238-024-01362-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 10.06.2024. Verfasst von Helge G Roider und 16 weiteren Autor:innen. Beteiligte Einrichtung: Bayer AG, Pharmaceuticals, Berlin, Germany. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Receptors, CCR8, Tumor Microenvironment. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Regulatory T cells (Tregs) are known to facilitate tumor progression by suppressing CD8+ T cells within the tumor microenvironment (TME), thereby also hampering the effectiveness of immune checkpoint inhibitors (ICIs). While systemic depletion of Tregs can enhance antitumor immunity, it also triggers undesirable autoimmune responses. Therefore, there is a need for therapeutic agents that selectively target Tregs within the TME without affecting systemic Tregs. In this study, as shown also by others, the chemokine (C–C motif) receptor 8 (CCR8) was found to be predominantly expressed on Tregs within the TME of both humans and mice, representing a unique target for selective depletion of tumor-residing Tregs. Based on this, we developed BAY 3375968, a novel anti-human CCR8 antibody, along with respective surrogate anti-mouse CCR8 antibodies, and demonstrated their in vitro mode-of-action through induction of potent antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities. In vivo, anti-mouse CCR8 antibodies effectively depleted Tregs within the TME primarily via ADCP, leading to increased CD8+ T cell infiltration and subsequent tumor growth inhibition across various cancer models. This monotherapeutic efficacy was significantly enhanced in combination with ICIs. Collectively, these findings suggest that CCR8 targeting represents a promising strategy for Treg depletion in cancer therapies. BAY 3375968 is currently under investigation in a Phase I clinical trial (NCT05537740).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bayer AG, Pharmaceuticals, Berlin, Germany.
- Bayer AG, Pharmaceuticals, San Francisco, USA.
- Bayer AG, Pharmaceuticals, Wuppertal, Germany.
- Current address: Roche Diagnostics GmbH, Penzberg, Germany.
- Current address: Memorial Sloan Kettering Cancer Center, New York, USA.
- Current address: Vincerx Pharma, Monheim am Rhein, Germany.
Zitieren
APA
Roider, H. G., Hoff, S., Tseng, S. Y., Berndt, S., Trautwein, M., Filarsky, K., Gritzan, U., Camps, J., Nadler, W. M., Grudzinska-Goebel, J., Ellinger, P., Pesch, T., Soon, C. F., Geyer, M., Gluske, K., Stelte-Ludwig, B., & Gorjánácz, M. (2024). Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clinical and Experimental Medicine, 24(1). https://doi.org/10.1007/s10238-024-01362-8
Vancouver
Roider HG, Hoff S, Tseng SY, Berndt S, Trautwein M, Filarsky K, et al. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clinical and Experimental Medicine. 2024;24(1). doi:10.1007/s10238-024-01362-8
BibTeX
@article{Roider2024,
author = {Roider, Helge G and Hoff, Sabine and Tseng, Su-Yi and Berndt, Sandra and Trautwein, Mark and Filarsky, Katharina and Gritzan, Uwe and Camps, Jordi and Nadler, Wiebke Maria and Grudzinska-Goebel, Joanna and Ellinger, Philipp and Pesch, Theresa and Soon, Chai Fen and Geyer, Marcel and Gluske, Katja and Stelte-Ludwig, Beatrix and Gorjánácz, Mátyás},
title = {Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody},
journal = {Clinical and Experimental Medicine},
year = {2024},
volume = {24},
number = {1},
doi = {10.1007/s10238-024-01362-8}
}
EUVIMED